Biogen Inc.
BIIBNASDAQHealthcare● Active
$195.67
+$0.33(+0.17%)
Market Cap$28.9B
P/E Ratio—
52W High$205.97
52W Low$121.05
Biogen Inc.（BIIB）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BIIB · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.81B | $9.68B | $9.84B | $10.17B | $10.98B |
| Cost of Revenue | $2.90B | $2.31B | $2.53B | $2.28B | $2.11B |
| Gross Profit | $6.91B | $7.37B | $7.30B | $7.90B | $8.87B |
| Gross Margin %(computed) | 70.47% | 76.12% | 74.24% | 77.61% | 80.79% |
| Operating Expenses | |||||
| R&D Expenses | $1.95B | $2.49B | $2.70B | $2.60B | $3.40B |
| G&A Expenses | $2.43B | $2.32B | $2.43B | $2.35B | $2.58B |
| Total Operating Expenses | $5.04B | $4.88B | $5.20B | $5.01B | $6.08B |
| Operating Income | $1.88B | $2.49B | $2.10B | $2.89B | $2.79B |
| Operating Margin %(computed) | 19.14% | 25.74% | 21.32% | 28.40% | 25.42% |
| Interest Income | $0.09B | $0.07B | $0.28B | $0.09B | $0.01B |
| Interest Expense | $0.25B | $0.25B | $0.25B | $0.25B | $0.25B |
| Income Before Tax | $1.40B | $1.91B | $1.30B | $3.59B | $1.78B |
| Income Tax Expense | $0.11B | $0.27B | $0.14B | $0.63B | $0.05B |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| Net Margin %(computed) | 13.18% | 16.87% | 11.81% | 29.95% | 14.17% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $8.85 | $11.20 | $8.02 | $20.97 | $10.44 |
| Wtd Avg Shares | 0.15B | 0.15B | 0.14B | 0.15B | 0.15B |
| EBITDA | $3.10B | $3.00B | $2.38B | $3.54B | $3.92B |
| EBITDA Margin %(computed) | 31.60% | 30.96% | 24.17% | 34.77% | 35.73% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Biogen Inc.
关于Biogen Inc.（BIIB）损益表
Biogen Inc.（BIIB）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，BIIB实现营收$9.81B，毛利润$6.91B（毛利率70.47%），净利润$1.29B（净利率13.18%）。
常见问题
BIIB · 4 问Biogen Inc.（BIIB）2025财年营收为$9.81B，同比up1.4%。
BIIB revenueBIIB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08